Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Inventory (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Inventory data on record, last reported at $185.9 million in Q3 2025.

  • For Q3 2025, Inventory rose 42.68% year-over-year to $185.9 million; the TTM value through Sep 2025 reached $185.9 million, up 42.68%, while the annual FY2024 figure was $153.7 million, 45.27% up from the prior year.
  • Inventory reached $185.9 million in Q3 2025 per AMPH's latest filing, down from $191.7 million in the prior quarter.
  • Across five years, Inventory topped out at $191.7 million in Q2 2025 and bottomed at $92.8 million in Q4 2021.
  • Average Inventory over 5 years is $120.9 million, with a median of $104.6 million recorded in 2023.
  • Peak YoY movement for Inventory: dropped 10.0% in 2021, then soared 60.59% in 2025.
  • A 5-year view of Inventory shows it stood at $92.8 million in 2021, then increased by 11.61% to $103.6 million in 2022, then grew by 2.17% to $105.8 million in 2023, then soared by 45.27% to $153.7 million in 2024, then rose by 20.94% to $185.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $185.9 million in Q3 2025, $191.7 million in Q2 2025, and $185.5 million in Q1 2025.